Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 2(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01170949Phase 2Terminated

Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria

Role: lead

NCT01481909Phase 2Completed

Study on Mastocytosis for Rupatadine Treatment

Role: lead

NCT01637116Completed

Profiling Urticaria for the Identification of Subtypes

Role: lead

NCT01444196Phase 4Completed

Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria

Role: lead

All 4 trials loaded